Top

Cancer Causes & Control

Published in:

01-12-2008 | Original Paper

Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery

Authors: Mary Anne Rossing, Kara L. Cushing-Haugen, Kristine G. Wicklund, Jennifer A. Doherty, Noel S. Weiss

Published in: Cancer Causes & Control | Issue 10/2008

Abstract

Objective

Some forms of ovarian neoplasms may be preventable through the removal of precursor lesions. We assessed the risk associated with a prior diagnosis of, and ovarian surgery following, ovarian cysts and endometriosis, with a focus on characterizing risk among tumor subgroups.

Methods

Information was collected during in-person interviews with 812 women with ovarian cancer diagnosed in western Washington State from 2002 to 2005 and 1,313 population-based controls. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Results

The risk of a borderline mucinous ovarian tumor associated with a history of an ovarian cyst was increased (OR=1.7, 95% CI: 1.0–2.8), but did not vary notably according to receipt of subsequent ovarian surgery. While risk of invasive epithelial ovarian cancer was slightly increased among women with a cyst who had no subsequent ovarian surgery, it was reduced when a cyst diagnosis was followed by surgery (OR = 0.6, 95% CI: 0.4–0.9). This reduction in risk was most evident for serous invasive tumors. Women with a history of endometriosis had a threefold increased risk of endometrioid and clear cell invasive tumors, with a lesser risk increase among women who underwent subsequent ovarian surgery.

Conclusions

Our results suggest differences in the relation of ovarian cysts and endometriosis with risk of specific subtypes of ovarian cancer as well as the possibility that ovarian surgery in women with these conditions may lower the risk of invasive disease.

Jordan SJ, Green AC, Whiteman DC, Webb PM (2007) Risk factors for benign, borderline and invasive mucinous ovarian tumors: Epidemiological evidence of a neoplastic continuum? Gynecol Oncol 107:223–230. doi:10.1016/j.ygyno.2007.06.006

Jordan S, Green A, Webb P (2006) Benign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk? Cancer Causes Control 17:623–632. doi:10.1007/s10552-005-0370-y PubMedCrossRef

Bell DA (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18(Suppl 2):S19-S32. doi:10.1038/modpathol.3800306

Ness RB (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189:280–294. doi:10.1067/mob.2003.408 PubMedCrossRef

Shih IM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518PubMed

Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5:35–44. doi:10.3121/cmr.2007.702 PubMedCrossRef

Crum CP, Drapkin R, Miron A et al (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19:3–9. doi:10.1097/GCO.0b013e328011a21f PubMedCrossRef

Brewer MA, Ranger-Moore J, Baruche A et al (2005) Exploratory study of ovarian intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 14:299–305. doi:10.1158/1055-9965.EPI-04-0212 PubMedCrossRef

Lee Y, Miron A, Drapkin R et al (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26–35. doi:10.1002/path.2091 PubMedCrossRef

10.

Gilks CB (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23:200–205. doi:10.1097/01.pgp. 0000130446.84670.93 PubMedCrossRef

11.

Scully RE (2000) Influence of origin of ovarian cancer on efficacy of screening. Lancet 355:1028–1029. doi:10.1016/S0140-6736(00)02026-2 PubMedCrossRef

12.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:2548–2556. doi:10.1158/1055-9965.EPI-07-0550 PubMedCrossRef

13.

Fritz AG, Percy C, Andrew J et al (2000) International classification of diseases for oncology ICD-O. World Health Organization, Geneva

14.

Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon

15.

Waksberg J (2000) Random digit dialing sampling for case-control studies. In: Gail MH, Benichou J (eds) Encyclopedia of epidemiologic methods. Wiley, New York, pp 749–753

16.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Weiss NS (2008) Cigarette smoking and risk of epithelial ovarian cancer. Cancer Causes Control 19:413–420PubMedCrossRef

17.

Weiss NS, Rossing MA (1996) Healthy screenee bias in epidemiologic studies of cancer incidence. Epidemiology 7:319–322PubMed

18.

Kreiger N, Sloan M, Cotterchio M, Parsons P (1997) Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol 26:710–715. doi:10.1093/ije/26.4.710 PubMedCrossRef

19.

Chiaffarino F, Parazzini F, Decarli A et al (2005) Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol 97:318–322. doi:10.1016/j.ygyno.2005.01.030 PubMedCrossRef

20.

Beard CM, Hartmann LC, Atkinson EJ et al (2000) The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935–1991. Ann Epidemiol 10:14–23. doi:10.1016/S1047-2797(99)00045-9 PubMedCrossRef

21.

Ness RB, Cramer DW, Goodman MT et al (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155:217–224. doi:10.1093/aje/155.3.217 PubMedCrossRef

22.

Parazzini F, Moroni S, La Vecchia C et al (1997) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33:1634–1637. doi:10.1016/S0959-8049(97)00011-7 PubMedCrossRef

23.

Dal Maso L, Canzonieri V, Talamini R, Franceschi S, La Vecchia C (2001) Origin of ovarian cancer from benign cysts. Eur J Cancer Prev 10:197–199. doi:10.1097/00008469-200104000-00016 PubMedCrossRef

24.

Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83:395–400. doi:10.1111/j.0001-6349.2004.00305.x PubMedCrossRef

25.

Crayford TJ, Campbell S, Bourne TH, Rawson HJ, Collins WP (2000) Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 355:1060–1063. doi:10.1016/S0140-6736(00)02038-9 PubMedCrossRef

26.

Brinton LA, Sakoda LC, Sherman ME et al (2005) Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 14:2929–2935. doi:10.1158/1055-9965.EPI-05-0394 PubMedCrossRef

27.

Kobayashi H, Sumimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43. doi:10.1111/j.1525-1438.2006.00754.x PubMedCrossRef

28.

Erzen M, Rakar S, Klancnik B, Syrjanen K (2001) Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 83:100–108. doi:10.1006/gyno.2001.6382 PubMedCrossRef

29.

Melin A, Sparen P, Persson I, Bergqvist A (2006) Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 21:1237–1242. doi:10.1093/humrep/dei462 PubMedCrossRef

Title: Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery
Authors: Mary Anne Rossing
Kara L. Cushing-Haugen
Kristine G. Wicklund
Jennifer A. Doherty
Noel S. Weiss
Publication date: 01-12-2008
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 10/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9207-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2008

Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions

Cigarette smoking, alcohol drinking, and risk of lymphoid neoplasms: results of a French case–control study

Assessing the impact of socio-economic status on cancer survival in New South Wales, Australia 1996–2001

Physical activity as a negative modulator of estrogen-induced breast cancer

Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study

Family history and age at onset of breast cancer in Hispanic and non-Hispanic white women

Keynote webinar | Spotlight on antibody–drug conjugates in cancer